Trump announces 100% chip tariff as Apple ups U.S. investment
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotech firm specializing in allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies, with a market capitalization of $242 million, has announced the presentation of new data at the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. According to InvestingPro analysis, the company maintains a strong liquidity position with a current ratio of 9.71, though it faces challenges with cash burn rates. The stock currently appears undervalued based on InvestingPro’s Fair Value metrics. The event, set for May 30-June 3 in Chicago, Illinois, will feature an oral presentation on ALLO-316, a treatment for renal cell carcinoma (RCC), and a poster on a pivotal Phase 2 trial for large B-cell lymphoma (LBCL).
The oral presentation will update on the Phase 1 TRAVERSE study of ALLO-316, an investigational AlloCAR T product targeting CD70, which is prevalent in RCC. This study suggests that ALLO-316 is the first allogeneic CAR T product to show promise in treating solid tumors. While analysts have revised earnings expectations upward for the upcoming period, InvestingPro data reveals the company is not expected to achieve profitability this year, with projected EPS of -$0.98 for FY2025. The presentation will focus on the Phase 1b expansion cohort where patients received a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million CAR T cells.
Additionally, a Trial-in-Progress poster will showcase the ALPHA3 trial’s design, which is evaluating cemacabtagene ansegedleucel (cema-cel) as a consolidation treatment for LBCL patients who are minimal residual disease (MRD) positive after first-line chemoimmunotherapy. This approach positions cema-cel as a potential "standard 7th cycle" of treatment for eligible patients with MRD.
Cema-cel, an anti-CD19 AlloCAR T™ product, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA in June 2022 for relapsed or refractory LBCL. The ALPHA3 trial, which began in June 2024, aims to establish cema-cel as a first-line consolidation therapy.
ALLO-316 also holds promise, having been granted RMAT designation in October 2024 for advanced or metastatic CD70+ RCC, following a Fast Track Designation in March 2023. The California Institute for Regenerative Medicine supports the ongoing TRAVERSE trial with ALLO-316 in RCC.
This information is based on a press release statement from Allogene Therapeutics. The company’s stock has experienced significant volatility, trading between $0.86 and $3.78 over the past 52 weeks. For deeper insights into Allogene’s financial health and detailed analysis, investors can access comprehensive research reports and additional ProTips through InvestingPro’s extensive coverage of over 1,400 US stocks.
In other recent news, Allogene Therapeutics reported a net loss of $59.7 million for the first quarter of 2025, which corresponds to a loss of $0.28 per share, closely aligning with analysts’ predictions of $0.2864 per share. The company maintains a robust cash position of $335.5 million and is actively working to expand its ALPHA3 trial internationally. Despite these efforts, Citizens JMP downgraded Allogene’s stock from Market Outperform to Market Perform, citing extended development timelines and lack of near-term milestones as reasons for the adjustment. The ALPHA3 development timeline has been pushed from mid-2025 to the first half of 2026, which has influenced the decision to remove ALLO-501A revenue projections from the valuation model.
The company’s enterprise value is currently negative, approximately -$88 million, and without the near-term catalyst of the ALPHA3 LD selection, the stock is expected to trade in line with the general market. Allogene’s strategic initiatives include expanding clinical trials and maintaining a strong cash position, which is crucial given the company’s projected cash burn of approximately $150 million for 2025. The company plans to provide proof of concept data for its ALLO-329 trial in the first half of 2026. Despite challenges, Allogene continues to focus on its innovative approaches in CAR T therapy, aiming to differentiate itself in various therapeutic areas, including oncology and autoimmune diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.